Opto Circuits subsidiary Eurocor showcases `drug-eluting balloon'

Opto Circuits (India) Ltd today said its subsidiary, Eurocor GmbH, has successfully showcased its `drug-eluting balloon Catheter' to Asian cardiologists.

Eurocor had presented convincing clinical results from its multi-center study, on 26 May, involving its Drug-Eluting-Balloon Catheter (DEB) at the EuroPCR conference in Paris.

EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI); it is the leading annual course contributing to
the advancement of education and information in the field of percutaneous coronary interventions and attracts over 11,500 attendees from the four corners of the globe, a company release said.

The results were presented as part of a late-breaking trial results, selected annually by the EuroPCR. The study compared the effectiveness of the Eurocor DIOR DEB device in combination with a bare metal stent vs other treatment options involving drug-eluting stents and uncoated balloon catheters.

The study results, as presented, clearly show very strong and significant clinical advantages provided by the DIOR DEB in bifurcated lesions with significantly reduced rates of binary restenosis as well as lower rates for MACE, TLR and TVR, the release said.

"Having launched the first CE-marked drug-eluting balloon catheter over two years ago, Opto's subsidiary Eurocor is a clear leader and innovator in this novel device space," says Vinod Ramnani, chairman and managing director of Opto Circuits (I). We are very pleased to hear that this fully randomised multi-center clinical study has validated our vision and belief in the DIOR DEB device", he added.